Brief: Organogenesis Q3 Net Product Revenue USD 150.5 Million
06/11/2025 21:05
Nov 06 (Reuters) - Organogenesis Q3 adjusted EBITDA USD 30.1 million. Q3 adjusted net income USD 23.2 million Q3 net income USD 21.6 million Q3 operating income USD 20.7 million outlook FY net income USD 8.6-25.4 million outlook FY EBITDA USD 19.1-41.9 million outlook FY adjusted EBITDA USD 45.5-68.3 million outlook FY adjusted net income USD 21.5-38.4 million
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers